Rapamycin (Sirolimus) and Rosuvastatin Interaction: Safety, Risks, and Clinical Guidance

Sirolimus (also called rapamycin, brand name Rapamune) is an mTOR inhibitor used as an FDA-approved immunosuppressant in kidney transplantation and, off-label, in low-dose intermittent regimens for aging-related research protocols. Rosuvastatin (brand name Crestor) is an HMG-CoA reductase inhibitor (statin) used to lower LDL cholesterol. The two drugs are commonly combined because sirolimus reliably raises lipid levels, and rosuvastatin is one of the more potent statins available.

This article covers a combination used in adults, mainly in transplant medicine and off-label longevity contexts. It is not a substitute for individualized dosing or diagnosis from the prescribing clinician.

Direct answer

Sirolimus and rosuvastatin can be prescribed together, and this combination appears routinely in transplant nephrology practice. The concern is not a documented catastrophic interaction but a plausible, mechanistically grounded increase in rosuvastatin exposure and myopathy risk, driven by sirolimus's inhibition of the OATP1B1 hepatic transporter that rosuvastatin depends on for liver uptake and clearance. Direct pharmacokinetic studies quantifying this specific pairing in humans are limited, so the practical response is conservative statin dosing plus creatine kinase (CK) and symptom monitoring rather than avoidance.

Why this combination comes up

Sirolimus is well established as a cause of dyslipidemia. The current Rapamune prescribing information lists hyperlipidemia and hypertriglyceridemia among the drug's characteristic adverse effects in transplant recipients (as noted in the current Rapamune prescribing information). The exact incidence figures vary by trial population and dose, and a reader relying on a specific percentage should check the current label text directly rather than trust a number carried over from a secondary summary.

In off-label, low-dose intermittent sirolimus protocols sometimes used outside transplant medicine, clinicians and researchers have reported LDL and triglyceride increases within the first months of use, but this use is not FDA-approved, and the magnitude of lipid change in that setting has not been established by controlled trial data available here. Any specific percentage attributed to that population should be treated as unverified until checked against a primary source.

Rosuvastatin is frequently chosen for its LDL-lowering potency relative to other statins, a comparison established in head-to-head statin trials such as STELLAR. The exact percentage reductions reported for each dose vary slightly by population and should be confirmed against the primary trial report rather than repeated as a fixed number; the directionally reliable point is that rosuvastatin at typical starting doses is among the more potent statins for LDL reduction.

The pharmacokinetic mechanism

Rosuvastatin depends heavily on hepatic uptake transporters, particularly OATP1B1 and OATP1B3, for entry into the liver, where the majority of the drug is cleared through biliary excretion rather than CYP450 metabolism. Sirolimus has been shown in vitro to inhibit OATP1B1. Because rosuvastatin's clearance depends on this transporter for hepatic uptake, inhibition of OATP1B1 is a pharmacologically plausible route by which sirolimus could raise circulating rosuvastatin concentrations.

This is a mechanistic and largely preclinical or indirect line of evidence. A dedicated human pharmacokinetic study directly measuring rosuvastatin exposure with and without concurrent sirolimus does not appear among the readily available primary literature reviewed for this page. By contrast, the interaction between cyclosporine (a calcineurin inhibitor and stronger OATP1B1 inhibitor) and rosuvastatin has been directly studied and shows a substantial increase in rosuvastatin exposure in transplant patients. Sirolimus is pharmacologically related to that finding only by analogy, not by a matching human PK study, so any specific fold-increase number for the sirolimus-rosuvastatin pair should be treated as unverified rather than quoted as established.

One related data point does exist for a sibling mTOR inhibitor: a study in renal transplant recipients compared the lipid-lowering effect of rosuvastatin versus fluvastatin in patients treated with everolimus, a different mTOR inhibitor closely related to sirolimus (Pihlstrom et al., 2014). That trial found rosuvastatin produced a more potent lipid-lowering effect than fluvastatin in everolimus-treated patients. This supports the general pattern that mTOR inhibitor-treated transplant recipients respond to statin therapy and that rosuvastatin performs well in this population, but it studied everolimus rather than sirolimus, and it addressed lipid efficacy, not muscle toxicity or a formal pharmacokinetic interaction. It should not be read as direct evidence of a sirolimus-rosuvastatin PK interaction.

There is also a theoretical P-glycoprotein and BCRP component, since sirolimus interacts with P-gp and rosuvastatin is a BCRP/P-gp substrate, but this compounding effect has not been directly quantified for this drug pair in the sources reviewed.

The pharmacodynamic overlap: two separate paths to muscle injury

Independent of any pharmacokinetic interaction, both drug classes carry their own recognized muscle risk:

• Statins are an established cause of myopathy, myalgia, and, rarely, rhabdomyolysis, through effects on skeletal muscle that are well documented in the statin safety literature.
• mTOR inhibitors like sirolimus suppress mTORC1 signaling, which plays a role in skeletal muscle protein synthesis; suppression of this pathway is biologically plausible as a contributor to muscle symptoms, though this is extrapolated from mechanistic and animal-model biology rather than a controlled human trial isolating sirolimus-specific muscle injury rates.

A retrospective claim comparing CK elevation rates between sirolimus-plus-statin and tacrolimus-plus-statin transplant patients has circulated in secondary summaries, but the specific study, patient count, and effect size could not be verified against a primary source for this draft and are therefore omitted rather than repeated as fact. A clinician relying on such a comparison should request the primary citation before using it to guide practice.

Combined, the mitochondrial effect of statins and the anti-anabolic effect of mTOR inhibition give a plausible biological rationale for additive muscle risk, even without a large dedicated outcomes trial proving the magnitude of that additive effect in humans.

Evidence-status assessment: what is actually known

What to verify before relying on a specific number: any exact percentage for sirolimus-associated LDL rise, any specific fold-increase in rosuvastatin exposure attributed to sirolimus, any cited retrospective CK-elevation comparison between sirolimus and tacrolimus statin combinations, and any attributed physician quotation. None of these could be confirmed against a primary source available for this draft.

Practical approach given the uncertainty

Because a direct, well-powered human interaction study for sirolimus plus rosuvastatin was not identified, the reasonable clinical approach mirrors general good practice for combining a statin with any moderate OATP1B1 inhibitor: start low, monitor, and treat symptoms as a trigger for labs rather than waiting for a scheduled visit.

• Obtain baseline CK, renal function (creatinine, eGFR), liver enzymes, and a fasting lipid panel before starting the combination.
• Favor a lower starting rosuvastatin dose in patients already on sirolimus, consistent with general statin prescribing caution in patients on interacting drugs or with reduced renal clearance, and titrate gradually with repeat labs rather than jumping to a high dose.
• Ask directly about new muscle pain, tenderness, weakness, or dark urine at each follow-up, and treat any of these as an indication for an urgent CK check rather than watchful waiting.
• Recheck renal function and lipids periodically; the exact interval used in transplant clinics varies by program, and readers should follow their own center's or clinician's monitoring schedule rather than a fixed number asserted here without a guideline citation.
• Consider pravastatin as an alternative for patients who develop myalgia on rosuvastatin, since pravastatin has lower OATP1B1 dependence and no CYP3A4 metabolism, though it is a weaker LDL-lowering agent and no dedicated head-to-head interaction trial with sirolimus was located either.
• Avoid simvastatin and lovastatin with sirolimus when possible; these statins are CYP3A4 substrates, and sirolimus is a CYP3A4 substrate and mild inhibitor, adding a metabolic interaction risk on top of any transporter effect.

When this requires urgent care

Unexplained new muscle pain, dark or tea-colored urine, or unusual weakness in a patient taking sirolimus and a statin together warrants prompt medical evaluation, including a CK level and assessment of kidney function. Rhabdomyolysis is uncommon with statin therapy generally, but a patient already on an immunosuppressant with a narrow therapeutic index has less physiologic reserve, and delayed evaluation carries more downside than an unnecessary lab draw.

Evidence boundary

Established: sirolimus causes dyslipidemia in transplant populations per FDA labeling; rosuvastatin is cleared primarily through OATP1B1-mediated hepatic uptake; cyclosporine (a different, stronger OATP1B1 inhibitor) substantially raises rosuvastatin exposure in transplant patients; rosuvastatin performs well for lipid lowering in everolimus-treated transplant patients specifically.

Plausible but unproven for this exact drug pair: that sirolimus meaningfully raises rosuvastatin plasma levels in humans by a specific magnitude; that the combination carries a quantifiable increase in rhabdomyolysis risk versus statin monotherapy; that separating dose timing reduces risk.

Not established: any precise numeric interaction magnitude, retrospective incidence comparison, or expert quotation attributed to this specific combination that could not be traced to a verifiable primary source.

Clinicians and pharmacists managing an individual patient should verify current product labeling, check an interaction database (such as Lexicomp or Micromedex) for the sirolimus-rosuvastatin entry, and confirm any numeric claim against the cited primary literature before using it in a clinical decision.